C Project
Resume:
In Chul (Calvin) Kim, Ph.D.
Myriad Pharmaceuticals
Salt Lake City, UT 84108
801-***-**** (Cell)
abj4pu@r.postjobfree.com
Sandy, UT 84093
. A talented and highly motivated medicinal chemist with 5 yrs of
experience in pharmaceutical industry.
. Contributed to the company's pipeline with 2 in the pre-clinical stage
and 1 in the phase-I clinical trial.
. Total synthesis of natural product during graduate research.
. A green card holder: authorized to work in the U.S.
Education
2003 - 2005 Postdoctoral Associate, Yale University, New Haven, CT
Bioorganic & Medicinal Chemistry
Professor Andrew D. Hamilton, Advisor
1998 - 2003 Ph.D., Department of Chemistry, Purdue University, West
Lafayette, IN
Synthetic Organic Chemistry
Professor Philip L. Fuchs, Advisor
1995 M.S. in Synthetic Organic Chemistry, Kyungpook National
University, S. Korea
1993 B.S. in Chemistry, Kyungpook National University, S. Korea
Professional Experience
2010-Present Myriad Pharmaceuticals, Medicinal Chemistry, Salt Lake
City, UT
Scientist II
. Co-led, designed, and synthesized a series of prodrugs of MPC-
3100, a HSP90 inhibitor which is now in phase I human
clinical trial. The water solubility was dramatically
increased and excellent pharmacokinetic profiles were
obtained to address an issue from the clinical trial.
Anticipating filing an IND in Q1, 2011.
. Responsible for submission, tracking and interpretation of
pharmacokinetic profiles.
2005-2010 Myriad Pharmaceuticals, Medicinal Chemistry, Salt Lake City, UT
Scientist I
. Anti-cancer kinase inhibitor projects:
. Designed and synthesized potent TTK & ALK kinase inhibitors
through hit-to-lead, lead optimization, and molecular
modeling studies to enhance potency and ADME profile in the
process of a drug discovery.
. Anti-cancer tubulin inhibitor backup project:
. Designed a series of backup compounds to achieve a good
oral bioavailabilty compared to Azixa which is an IV drug
and in phase II human clinical trial. MPI-0463803 showed an
excellent oral bioavailability with maintaining equal
potency and BBB penetration of Azixa. It is now in the
company's pipeline at a preclinical stage.
. Anti-HIV maturation and fusion projects:
. Designed and synthesized potent anti-HIV compounds based
on structure-activity relationships through a lead
optimization process.
. Significantly contributed to the success of the project to
file an IND of an anti-maturation compound which was named
as Vivicon.
. Led anti-HIV fusion project by designing potentially potent
compounds and tackling a challenging issue of oral
bioavailability using a pro-drugging strategy. Discovered an
IND candidate (MPI-0471936) and it is now in the company's
pipeline at a preclinical stage.
. Responsible for submission, tracking and interpretation of
PAMPA and pharmacokinetic data.
2003-2005 Postdoctoral Associate, Department of Chemistry
Yale University, New Haven, CT
. Accomplished the synthesis of an indane-containing terphenyl
scaffold which has tremendous synthetic challenges and
represents i, i+3, i+4, and i+7 groups of an ?-helix in
critical protein-protein interactions for proteomimetics
using ?-Helix mimicry.
. Design and synthesis of oligomeric non-fluorous CO2-soluble
materials starting from acetoxyoxetane.
1998-2003 Graduate Research Assistant, Department of Chemistry
Purdue University, West Lafayette, IN
. Studies toward the enantioselective total synthesis of
rhizoxin D.
. Developed a methodology of the asymmetric synthesis of
polypropionate stereopentads via functionality propagation by
alkylative oxidation of cross-conjugated dienyl sulfones.
1995-1998 LG Biotech Research Institute, LG Chemical Ltd., Daejon, S.
Korea
Senior Research Associate, Medicinal Chemistry
. Synthesis of thrombin inhibitors.
. Combinatorial approach for novel synthesis of benzamidine
library using solid-phase synthesis.
Publications
1. Reeder, M.; Suzuki, K.; Kim, I. C.; Halter, R. J.; Anderson, M. B.;
Carlson, R.; Baichwal, V.; Pleiman, C. M.; Mather, G. G.; Jessing, K.;
Willardsen, J. A. "Discovery of 2-methyl-N-(4-methoxyphenyl)-N-
methylquinazolin-4-amine as a potent inducer of apoptosis with high in
vivo activity." Manuscript in preparation.
2. Gerrish, D.; Kim, I. C.; Kumar, D. V.; Austin, A.; Garrus, J.;
Baichwal, V.; Saunders, M.; Anderson, M. B.; Carlson, R.; Arranz-Plaza,
E.; Yager, K. M. "Triterpene based compounds with potent anti-
maturation activity against HIV-1." Bioorg. Med. Chem. Lett. 2008, 18,
6377-6380.
3. Wang, Y.; Hong, L; Tapriyal, D.; Kim, I. C.; Paik, I.; Crosthwaite, J.
M.; Hamilton, A. D.; Thies, M. C.; Beckman, E. J.; Enick, R. M.;
Johnson, J. K. "Design and evaluation of non-fluorous CO2-soluble
polymers." Macromolecules, submitted.
4. Kim, I. C.; Hamilton, A. D. "Diphenylindane-based proteomimetics
reproduce the projection of the i, i+3, i+4, and i+7 residues on an ?-
helix." Org. Lett. 2006, 8, 1751-1754.
5. Torres, E.; Chen, Y.; Kim, I. C.; Fuchs, P. L. "Functionality
propagation by alkylative oxidation of cross-conjugated
cycloheptadienyl sulfones." Angew. Chem. Int. Ed. 2003, 42, 3124-3131.
6. Lee, K.; Jung, W.; Park C. W.; Hong, C. Y.; Kim, I. C.; Kim, S.; Oh,
Y. S.; Kwon, O. H.; Lee, S.; Park, H. D.; Kim, S. W.; Lee, Y. H.; Yoo,
Y. J. "Benzylamine-based selective and orally bioavailable inhibitors
of thrombin." Bioorg. Med. Chem. Lett. 1998, 8, 2563-2568.
7. Kim, H. S.; Kim, I. C.; Lee, S. O. "Synthesis of two marine natural
products: The aglycones of pavoninin-1 and -2." Tetrahedron 1997, 53,
8129-8136.
8. Kim, H. S.; Kim, D. I.; Oh, S. H.; Kim, I. C. "Chemical synthesis of
15-ketosterols and their inhibitions of cholesteryl ester transfer
protein." Bioorg. Med. Chem. 1995, 3, 367-374.
Patents
1. Kumar, D. V.; McAlexander, I.; Slattum, P.; Zigar, Z.; Kim, I. C.;
Saunders, M.; Gerrish, D. A.; Willardsen, A.; Shendrovich, M.
"Compounds and therapeutic use and thereof." U.S. Provisional Pat.
Appl. ( kinase Inhibitors)
2. Anderson, M. B.; Willardsen, J. A.; Weiner, W. S.; Suzuki, K.; Halter,
R. J.; Kim, I. C.; Reeder, M.; Yungai, A. "Pharmaceutical compounds as
inhibitors of cell proliferation and the use thereof." U.S. Provisional
Pat. Appl.
3. Yager, K. M.; Kim, I. C.; Saunders, M.; Gerrish, D. A.; Kumar, D. V.;
Anderson, M. B. "Antiviral compounds and use thereof." PCT Int. Appl.,
WO 2008/127364.
4. Yager, K. M.; Arranz-Plaza, E.; Kumar, D. V.; Kim, I. C. "Compounds
for treating viral infections." PCT Int. Appl., WO 2008/115281.
5. Yager, K. M.; Kim, I. C.; Gerrish, D. A.; Anderson, M. B. "Antiviral
compounds and use thereof." PCT Int. Appl., WO 2008/097341.
6. Arranz-Plaza, E.; Yager, K. M.; Gerrish, D. A.; Anderson, M. B.; Kim,
I. C.; Kumar, D. V. "Antiviral compounds." PCT Int. Appl., WO
2007/002411.
7. Fuchs, P. L.; Meyers, D.; Torres, E.; Park, T.; Kim, I. C.; Chen, Y.;
Lantrip, D.; Evarts, J. B. "Chemical synthons and intermediates." U.S.
Pat. Appl., US 2004/0138485.
8. Hong, C. Y.; Kim, I. C.; Kim, Y. K.; Lee, G.; Jung, W. H.; Park, C.
W.; Yoo, Y. J. "Highly potent and orally administrable thrombin
inhibitors." Korean IPO, (1998), KR 100242264.
Invited Journal Review
1. Hymavathi, A. et al. Bioactivity-guided isolation of cytotoxic
constituents from stem-bark of Premna tomentosa. Bioorg. Med. Chem.
Lett. 2009, BMCL-D-09-01039.
Presentations
1. Kim, I. C.; Fuchs, P. L.: Synthesis of two key segments of rhizoxin
from chiral carbon catalog of cycloheptyl sulfone. ACS National
Meeting, Boston, MA, Aug. 2002, ORGN 363.
2. Kim, I. C.; Kim, H. S.: Synthesis of marine natural products aglycone
pavoninin-1 and -2. Korean Chemical Society National Meeting, Seoul,
Korea, March 1994.
References
Available upon request
Contact this candidate